JP2019510078A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510078A5
JP2019510078A5 JP2018563405A JP2018563405A JP2019510078A5 JP 2019510078 A5 JP2019510078 A5 JP 2019510078A5 JP 2018563405 A JP2018563405 A JP 2018563405A JP 2018563405 A JP2018563405 A JP 2018563405A JP 2019510078 A5 JP2019510078 A5 JP 2019510078A5
Authority
JP
Japan
Prior art keywords
seq
sequence
formulation
antibody
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510078A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/019131 external-priority patent/WO2017147293A1/en
Publication of JP2019510078A publication Critical patent/JP2019510078A/ja
Publication of JP2019510078A5 publication Critical patent/JP2019510078A5/ja
Priority to JP2022058898A priority Critical patent/JP2022084922A/ja
Pending legal-status Critical Current

Links

JP2018563405A 2016-02-23 2017-02-23 Il−6アンタゴニスト製剤およびその使用 Pending JP2019510078A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022058898A JP2022084922A (ja) 2016-02-23 2022-03-31 Il-6アンタゴニスト製剤およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298774P 2016-02-23 2016-02-23
US62/298,774 2016-02-23
PCT/US2017/019131 WO2017147293A1 (en) 2016-02-23 2017-02-23 Il-6 antagonist formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022058898A Division JP2022084922A (ja) 2016-02-23 2022-03-31 Il-6アンタゴニスト製剤およびその使用

Publications (2)

Publication Number Publication Date
JP2019510078A JP2019510078A (ja) 2019-04-11
JP2019510078A5 true JP2019510078A5 (https=) 2020-03-26

Family

ID=59685584

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563405A Pending JP2019510078A (ja) 2016-02-23 2017-02-23 Il−6アンタゴニスト製剤およびその使用
JP2022058898A Pending JP2022084922A (ja) 2016-02-23 2022-03-31 Il-6アンタゴニスト製剤およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022058898A Pending JP2022084922A (ja) 2016-02-23 2022-03-31 Il-6アンタゴニスト製剤およびその使用

Country Status (11)

Country Link
US (2) US20190046642A1 (https=)
EP (1) EP3419599A4 (https=)
JP (2) JP2019510078A (https=)
KR (1) KR20180116359A (https=)
CN (1) CN108718522A (https=)
AR (1) AR107708A1 (https=)
AU (1) AU2017223687A1 (https=)
BR (1) BR112018017031A2 (https=)
CA (1) CA3012350A1 (https=)
MX (1) MX2018010032A (https=)
WO (1) WO2017147293A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4621067A3 (en) 2017-05-05 2025-11-19 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
BR112020010761A2 (pt) * 2017-11-30 2020-11-24 Bio-Thera Solutions, Ltd. formulação líquida de anticorpo humanizado para o tratamento de doenças relacionadas à il-6
JP7407723B2 (ja) * 2018-09-14 2024-01-04 田辺三菱製薬株式会社 ヒト抗il-33モノクローナル抗体含有医薬用組成物
KR102917813B1 (ko) * 2018-10-31 2026-01-26 리히터 게데온 닐트. 수성 약학 제제
EP4591885A3 (en) * 2019-05-01 2025-11-19 Novo Nordisk A/S Anti-il-6 antibody formulation
MX2022010320A (es) * 2020-02-21 2023-01-30 Spitfire Pharma Llc Agonistas, formulaciones y metodos de uso de glp-1r y gcgr.
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
EP4172351A4 (en) * 2020-06-26 2024-08-14 Trefoil Therapeutics, Inc. RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THERAPEUTIC USES THEREOF
WO2022026914A1 (en) * 2020-07-31 2022-02-03 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN116261448A (zh) * 2020-08-19 2023-06-13 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂
KR20220028972A (ko) * 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
US12600764B2 (en) * 2021-08-27 2026-04-14 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (COV) variants
JP2023042974A (ja) * 2021-09-15 2023-03-28 シスメックス株式会社 抗サイトカイン抗体の抗原に対する親和性を向上させる方法、抗サイトカイン抗体の製造方法及び抗サイトカイン抗体
CN114525235B (zh) * 2022-02-25 2023-07-14 郑州大学 一种提高人表皮生长因子分泌生产效率的方法
JP2025534333A (ja) * 2022-09-30 2025-10-15 ソネット バイオセラピューティクス,インコーポレイテッド 低用量il-6製剤およびその使用方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック,インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
JP5290489B2 (ja) 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Igg抗体の安定な液体医薬製剤
WO2003094888A1 (en) 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Processes for forming a drug delivery device
EP1572103A4 (en) 2002-11-15 2008-02-13 Centocor Inc ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
SG166768A1 (en) 2003-12-23 2010-12-29 Rinat Neuroscience Corp Agonist anti-trkc antibodies and methods using same
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DK2021463T3 (en) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Culture method to obtain a cloned population of antigen-specific B cells
CN101605532A (zh) 2007-02-16 2009-12-16 惠氏公司 含有山梨糖醇的蛋白质调配物
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
HUE037932T2 (hu) * 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
CN101925611A (zh) 2007-11-21 2010-12-22 安姆根有限公司 Wise结合剂和表位
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
WO2009090189A1 (en) 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
US8657211B2 (en) 2008-09-12 2014-02-25 Kdf Co., Ltd. Water spouting device
US20120005773A1 (en) * 2008-10-01 2012-01-05 Aasen Eric D Transgenic plants with enhanced agronomic traits
US8992920B2 (en) * 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
CN102224169A (zh) 2008-11-26 2011-10-19 葛兰素集团有限公司 多肽、抗体可变结构域和拮抗剂
CN104119438A (zh) * 2009-01-29 2014-10-29 米迪缪尼有限公司 延长体内半衰期的人抗il-6抗体及其在治疗肿瘤、自身免疫性疾病和炎症性疾病中的应用
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2012007896A1 (en) 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
MX2014006673A (es) 2011-12-07 2014-09-04 Amgen Inc Separacion de la isoforma de disulfuro de la igg2.
AU2013267310A1 (en) 2012-06-01 2014-12-11 Ophthotech Corporation Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
WO2014039903A2 (en) * 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Stable aqueous formulations of adalimumab
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
AU2014286996A1 (en) * 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
PT3215530T (pt) * 2014-11-07 2019-11-21 Sesen Bio Inc Anticorpos de il-6 melhorados

Similar Documents

Publication Publication Date Title
JP2019510078A5 (https=)
US20260098085A1 (en) Methods for treating age-related macular degeneration
JP2014532072A5 (https=)
KR20200131839A (ko) 안질환의 치료 방법
JP2016504416A5 (https=)
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
AU2017299581A1 (en) Humanized monoclonal antibodies that target ve-ptp (hptp-β)
RU2016145136A (ru) РЕКОМБИНАНТНЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА vNAR, НЕЙТРАЛИЗУЮЩИЕ ФАКТОР РОСТА ЭНДОТЕЛИЯ СОСУДОВ (VEGF)
JP7828274B2 (ja) 眼疾患を治療するための方法
JP2018536650A5 (https=)
TW202237181A (zh) 治療眼部疾病之方法
WO2018195912A1 (zh) 一种眼用药物组合物及其用途
Erichev et al. Evaluating the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration and concomitant glaucoma
WO2020022438A1 (ja) 網膜線維化を伴う眼疾患の処置剤
JP2026072102A (ja) 眼疾患を治療するための方法
RU2771900C2 (ru) Способ лечения болезней глаз
RU2022102753A (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
CN120204358A (zh) 一种含有抗vegf的融合蛋白的药物组合物
RU2024102531A (ru) Состав на основе раствора белка, содержащий антитело к vegf в высокой концентрации
RU2020137402A (ru) Способы лечения заболевания с использованием забуференных составов бевацизумаба
NZ731090B2 (en) Improved il-6 antibodies